Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 527

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

Jinjun Cheng, Elaine S. Jaffe

Blood (2019) 134 (24): 2226.

https://doi.org/10.1182/blood.2019003455

Published: 2019

Journal Articles

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Edward Briercheck, MD, Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Oscar Silva, MD PhD, Maneka Puligandla, MS, Marcos Mauricio Siliézar Tala, MD, Timothy Guyon, MSc, Samuel L. Dixon, BS, Robert Terbrueggen, PhD, Yasodha Natkunam, MD PhD, Kristen E. Stevenson, MS, David M Weinstock

Blood (2019) 134 (Supplement_1): 409.

https://doi.org/10.1182/blood-2019-121397

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Shi Hui Clarice Choong, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD, Sanjay De Mel, BSc, BM, Te-Chih Liu, FRCPath, MBBS, MRCP, Bei Jenny Li, Li Mei Michelle Poon, Shir Ying Lee, FRCPath,MBBS,MRCP,, Hoon Chung Tae, Rebecca Teng, Seok Wei Stephrene Chan

Blood (2019) 134 (Supplement_1): 5253.

https://doi.org/10.1182/blood-2019-125241

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Marcio M Andrade-Campos, MD PhD, Antonio Salar, MD PhD, Blanca Sanchez-Gonzalez, MD, Concepción Fernández-Rodríguez, Eva Gimeno, MD PhD, L Ruiz, Gabriel Piquer, Francesc Garcia-Pallarols, BSc, Natalia Papaleo, MD, Ivonne Vazquez, Lluís Colomo, MD PhD, Beatriz Bellosillo, PhD

Blood (2019) 134 (Supplement_1): 492.

https://doi.org/10.1182/blood-2019-131081

Published: 2019

Journal Articles

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, MD, Grzegorz Nowakowski, MD, Jan Endell, Rainer Boxhammer

Blood (2019) 134 (Supplement_1): 5345.

https://doi.org/10.1182/blood-2019-129600

Published: 2019

Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5256.

https://doi.org/10.1182/blood-2019-122629

Published: 2019

Journal Articles

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Ajay K. Gopal, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Edus H. Warren, MD PhD, Chaitra S. Ujjani, MD, Mazyar Shadman, MD, Stephen D. Smith, MD, Brian G. Till, MD, Jonathan R. Fromm, MD PhD, Andrei R Shustov, MD, Qian Vicky Wu, PhD, Manoj P. Menon, MD

Blood (2019) 134 (Supplement_1): 5258.

https://doi.org/10.1182/blood-2019-124984

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Chandler Graf, Anita Sultan, MD, Donald P. Quick, MD, Bradley J. Grant, JD, Sriman Swarup, MDMBBS, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Sanjay Awasthi, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5876.

https://doi.org/10.1182/blood-2019-123297

Published: 2019

Journal Articles

From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology

Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): SCI-47.

https://doi.org/10.1182/blood-2019-121067

Published: 2019

NARROW

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

A Window Study of Ixazomib in Untreated B-NHL

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only